December 08, 2021
Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.
December 07, 2021
Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.
October 27, 2021
Patients with relapsed/refractory myeloma continued to experience durable and efficacious responses after treatment with ciltacabtagene autoleucel.
September 21, 2021
Patients with extensive-stage small cell lung cancer (ES-SCLC) derived overall survival benefit from a combination of durvalumab and chemotherapy.
September 21, 2021
Consistent Ki67 suppression with giredestrant was noted in a phase 2 trial versus anatrozole.
September 19, 2021
Data from the phase 3 MONALEESA-2 trial demonstrate significant benefit of frontline ribociclib (Kisqali) added to letrozole for hormone receptor–positive, HER2-negative advanced breast cancer
September 16, 2021
Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.
September 08, 2021
Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.
June 07, 2021
Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.
June 06, 2021
Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.